The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Fluticasone / Formoterol (Flutiform k-haler®) has been accepted for use in the regular treatment of asthma where the use of a combination product is an appropriate treatment. This inhaler is a breath-actuated inhaler that is bioequivalent to Flutiform metered-dose inhaler (pMDI) and costs the same.
Eslicarbazepine (Zebinix®) has been rejected for use as monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. The manufacturer failed to make a submission for this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
During May 2018 Clinical Knowledge Summaries were updated in the following areas.
The following topics were all reviewed:
The majority of topics have undergone reviews and minor restructures.
The most significant changes are to the Fungal skin infection - scalp and Smoking cessation topics. The Fungal skin infection - scalp topic has had complications and prognosis nodes added to the background information section and a differential diagnosis node has been added to the diagnosis section. The Smoking cessation topic has had information added on very brief advice on smoking cessation for adults and pregnant women and recommendations regarding e-cigarettes have been added.
Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.